222 related articles for article (PubMed ID: 34279685)
1. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.
Zhuang H; Chen X; Wang Y; Huang S; Chen B; Zhang C; Hou B
Cancer Immunol Immunother; 2022 Mar; 71(3):601-612. PubMed ID: 34279685
[TBL] [Abstract][Full Text] [Related]
2. B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8
Zhuang H; Zhou Z; Zhang Z; Chen X; Ma Z; Huang S; Gong Y; Zhang C; Hou B
Aging (Albany NY); 2020 Dec; 13(2):2310-2329. PubMed ID: 33316775
[TBL] [Abstract][Full Text] [Related]
3. FLNB overexpression promotes tumor progression and associates with immune suppression, evasion and stemness in pancreatic cancer.
Fan G; Yan Q; Chen Y; Han M; Wu Z; Ruan S; Zhuang H; Gou Q; Hou B
Am J Cancer Res; 2024; 14(2):709-726. PubMed ID: 38455418
[TBL] [Abstract][Full Text] [Related]
4. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
[TBL] [Abstract][Full Text] [Related]
5. FAM83H overexpression predicts worse prognosis and correlates with less CD8
Zhuang H; Zhang C; Hou B
Clin Transl Oncol; 2020 Dec; 22(12):2244-2252. PubMed ID: 32424701
[TBL] [Abstract][Full Text] [Related]
6. GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer.
Zhuang H; Zhang C; Hou B
Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32936232
[TBL] [Abstract][Full Text] [Related]
7. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.
Tang P; Qu W; Wu D; Chen S; Liu M; Chen W; Ai Q; Tang H; Zhou H
J Immunol Res; 2021; 2021():3821055. PubMed ID: 34993253
[TBL] [Abstract][Full Text] [Related]
8. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
9. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
10. Development of an autophagy-related signature in pancreatic adenocarcinoma.
Yue P; Zhu C; Gao Y; Li Y; Wang Q; Zhang K; Gao S; Shi Y; Wu Y; Wang B; Xie J; Meng X
Biomed Pharmacother; 2020 Jun; 126():110080. PubMed ID: 32203889
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer cell-derived microRNA-155-5p-containing extracellular vesicles promote immune evasion by triggering EHF-dependent activation of Akt/NF-κB signaling pathway.
Wang S; Gao Y
Int Immunopharmacol; 2021 Nov; 100():107990. PubMed ID: 34482266
[TBL] [Abstract][Full Text] [Related]
12. Identification of
Li Z; Zhuang H; Chen X; Zhang Y; Ma Z; Wang S; Yan Q; Zhou Z; Huang S; Zhang C; Hou B
J Oncol; 2022; 2022():4269733. PubMed ID: 35571489
[TBL] [Abstract][Full Text] [Related]
13. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
[TBL] [Abstract][Full Text] [Related]
14. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.
Chen Y; Wang C; Song J; Xu R; Ruze R; Zhao Y
Front Immunol; 2021; 12():758004. PubMed ID: 34887861
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer.
Zhou X; Zhu X; Yao J; Wang X; Wang N
Invest New Drugs; 2021 Dec; 39(6):1469-1483. PubMed ID: 33983530
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.
Zou W; Li L; Wang Z; Jiang N; Wang F; Hu M; Liu R
Bioengineered; 2021 Dec; 12(1):9006-9020. PubMed ID: 34654352
[TBL] [Abstract][Full Text] [Related]
18. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
19. Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer.
Wang C; Chen Y; Xinpeng Y; Xu R; Song J; Ruze R; Xu Q; Zhao Y
BMC Cancer; 2022 Aug; 22(1):879. PubMed ID: 35953822
[TBL] [Abstract][Full Text] [Related]
20. CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and
Yu Y; Wang Y; Zou Y; Yu Y
Dis Markers; 2022; 2022():5286820. PubMed ID: 35707714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
